No Data Yet
The ulcerative colitis treatment market is projected for significant growth through 2034, driven by a rising prevalence of 1.5 million diagnosed U.S. cases in 2024 and a strong pipeline of novel therapies.
Unconfirmed reports suggest Eli Lilly may acquire Abivax, whose stock is buoyed by strong Phase 3 results for its ulcerative colitis drug, obefazimod. This follows Lilly's own clinical success with its obesity treatment, retatrutide, positioning it for strategic acquisitions.